One study reported that pediatric CBF fusion AML patients with both CSF3R and KIT mutations had worse outcomes than those with either mutation alone did, which aligns with our observation that targeting KIT might have helped some of our CBF‐rearranged/CSF3R patients [21]. This evidence concerns the gene CEBPZ and acute myeloid leukemia.